Guidelines| Volume 88, ISSUE 1, P10-19, July 2008

Download started.


Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group


      Background and purpose

      Three randomised trials have demonstrated the benefit of adjuvant post-prostatectomy radiotherapy (PPRT) for high risk patients. Data also documents the effectiveness of salvage radiotherapy following a biochemical relapse post-prostatectomy. The Radiation Oncology Genito-Urinary Group recognised the need to develop consensus guidelines on to whom, when and how to deliver PPRT.

      Materials and methods

      Draft guidelines were developed and refined at a consensus conference in June 2006 attended by 63 delegates where urological, radiotherapy and diagnostic imaging experts spoke on aspects of PPRT. Unresolved issues were further developed by working parties and redistributed until consensus was reached.


      Central to the recommendations is that patients with positive surgical margins, seminal vesicle invasion and/or extracapsular extension have a high risk of residual local disease and should be informed of the options of either immediate adjuvant radiotherapy or active surveillance with early salvage in the event of biochemical recurrence. Salvage radiotherapy should be instituted at the earliest confirmation of biochemical recurrence. Detailed contouring guidelines have been developed, defining the regions at risk of residual microscopic disease which should be included in the clinical target volume. The recommended doses are 60–64 Gy for adjuvant, and 60–66 Gy for salvage radiotherapy. The role of hormone therapy in conjunction with PPRT is yet to be defined.


      These consensus guidelines have been developed to give clinical and technical guidance to radiation oncologists and urologists in the management of high risk post-prostatectomy patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bolla M.
        • van Poppel H.
        • Collette L.
        • et al.
        Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).
        Lancet. 2005; 366: 572-578
        • Thompson Jr., I.M.
        • Tangen C.M.
        • Paradelo J.
        • et al.
        Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
        JAMA. 2006; 296: 2329-2335
        • Wiegel T.
        • Bottke D.
        • Willich N.
        • et al.
        Phase III results of adjuvant radiotherapy (RT) versus “wait and see” in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95).
        J Clin Oncol. 2005; 23: 4513
        • Do L.V.
        • Do T.M.
        • Smith R.
        • Parker R.G.
        Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival.
        Am J Clin Oncol. 2002; 25: 1-8
        • Choo R.
        • Hruby G.
        • Hong J.
        • et al.
        Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?.
        Int J Radiat Oncol Biol Phys. 2002; 52: 674-680
        • Leibovich B.C.
        • Engen D.E.
        • Patterson D.E.
        • et al.
        Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin.
        J Urol. 2000; 163: 1178-1182
        • Vicini F.A.
        • Ziaja E.L.
        • Kestin L.L.
        • et al.
        Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer.
        Urology. 1999; 54: 111-117
      1. National Health and Medical Research Council (NHMRC) publication: Guidelines for the development and implementation of clinical practice guidelines. Canberra: NHMRC; 1995.

        • Han M.
        • Partin A.W.
        • Pound C.R.
        • Epstein J.I.
        • Walsh P.C.
        Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.
        Urol Clin North Am. 2001; 28: 555-565
        • Hull G.W.
        • Rabbani F.
        • Abbas F.
        • Wheeler T.M.
        • Kattan M.W.
        • Scardino P.T.
        Cancer control with radical prostatectomy alone in 1,000 consecutive patients.
        J Urol. 2002; 167: 528-534
        • Pound C.R.
        • Partin A.W.
        • Eisenberger M.A.
        • Chan D.W.
        • Pearson J.D.
        • Walsh P.C.
        Natural history of progression after PSA elevation following radical prostatectomy.
        JAMA. 1999; 281: 1591-1597
        • Stephenson A.J.
        • Scardino P.T.
        • Eastham J.A.
        • et al.
        Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.
        J Clin Oncol. 2005; 23: 7005-7012
        • Catalona W.J.
        • Smith D.S.
        5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer.
        J Urol. 1994; 152: 1837-1842
        • Kupelian P.A.
        • Katcher J.
        • Levin H.S.
        • Klein E.A.
        Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
        Int J Radiat Oncol Biol Phys. 1997; 37: 1043-1052
        • Pound C.R.
        • Partin A.W.
        • Epstein J.I.
        • Walsh P.C.
        Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
        Urol Clin North Am. 1997; 24: 395-406
        • Swindle P.
        • Eastham J.A.
        • Ohori M.
        • et al.
        Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
        J Urol. 2005; 174: 903-907
        • Epstein J.I.
        • Partin A.W.
        • Sauvageot J.
        • Walsh P.C.
        Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up.
        Am J Surg Pathol. 1996; 20: 286-292
        • Palapattu G.S.
        • Allaf M.E.
        • Trock B.J.
        • Epstein J.I.
        • Walsh P.C.
        Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
        J Urol. 2004; 172: 1860-1864
        • Collette L.
        • van Poppel H.
        • Bolla M.
        • et al.
        Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911).
        Eur J Cancer. 2005; 41: 2662-2672
      2. Tombal B, Debie B, Scaillet P, Van Cangh P. Immediate external beam radiation therapy (EBRT) after radical prostatectomy (PCa): long-term influence on QOL, urinary, and rectal symptoms. In: ASCO Prostate Cancer Symposium; 2006 [Abs. No. 123].

        • Cadeddu J.A.
        • Partin A.W.
        • DeWeese T.L.
        • Walsh P.C.
        Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.
        J Urol. 1998; 159: 173-177
        • Pisansky T.M.
        • Kozelsky T.F.
        • Myers R.P.
        • et al.
        Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.
        J Urol. 2000; 163: 845-850
        • Anscher M.S.
        • Clough R.
        • Dodge R.
        Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years.
        Int J Radiat Oncol Biol Phys. 2000; 48: 369-375
        • Katz M.S.
        • Zelefsky M.J.
        • Venkatraman E.S.
        • Fuks Z.
        • Hummer A.
        • Leibel S.A.
        Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.
        J Clin Oncol. 2003; 21: 483-489
        • Stephenson A.J.
        • Shariat S.F.
        • Zelefsky M.J.
        • et al.
        Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
        JAMA. 2004; 291: 1325-1332
        • Pazona J.F.
        • Han M.
        • Hawkins S.A.
        • Roehl K.A.
        • Catalona W.J.
        Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates.
        J Urol. 2005; 174: 1282-1286
        • Stephenson A.J.
        • Slawin K.M.
        The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy.
        Nat Clin Pract Urol. 2004; 1: 90-96
        • Stephenson A.J.
        • Kattan M.W.
        • Eastham J.A.
        • et al.
        Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.
        J Clin Oncol. 2006; 24: 3973-3978
        • MacDonald O.K.
        • Schild S.E.
        • Vora S.
        • et al.
        Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?.
        Urology. 2004; 64: 760-764
        • Nudell D.M.
        • Grossfeld G.D.
        • Weinberg V.K.
        • Roach 3rd, M.
        • Carroll P.R.
        Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns.
        Urology. 1999; 54: 1049-1057
        • Duchesne G.M.
        • Dowling C.
        • Frydenberg M.
        • et al.
        Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study.
        Urology. 2003; 61: 179-183
        • Maier J.
        • Forman J.
        • Tekyi-Mensah S.
        • Bolton S.
        • Patel R.
        • Pontes J.E.
        Salvage radiation for a rising PSA following radical prostatectomy.
        Urol Oncol. 2004; 22: 50-56
        • Cookson M.S.
        • Aus G.
        • Burnett A.L.
        • et al.
        Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
        J Urol. 2007; 177: 540-545
        • Zelefsky M.J.
        • Aschkenasy E.
        • Kelsen S.
        • Leibel S.A.
        Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy.
        Int J Radiat Oncol Biol Phys. 1997; 39: 327-333
        • Van Cangh P.J.
        • Richard F.
        • Lorge F.
        • et al.
        Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study.
        J Urol. 1998; 159: 164-166
        • Syndikus I.
        • Pickles T.
        • Kostashuk E.
        • Sullivan L.D.
        Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control.
        J Urol. 1996; 155: 1983-1986
        • Formenti S.C.
        • Lieskovsky G.
        • Skinner D.
        • Tsao-Wei D.D.
        • Groshen S.
        • Petrovich Z.
        Update on impact of moderate dose of adjuvant radiation on urinary continence and sexual potency in prostate cancer patients treated with nerve-sparing prostatectomy.
        Urology. 2000; 56: 453-458
        • Stephenson A.J.
        • Pollack A.
        • Kattan M.W.
        • Scardino P.T.
        Post-Prostatectomy Radiotherapy Consortium. Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
        J Clin Oncol. 2006; 24 ([Meeting abstracts]): 4514
        • Elias S.
        • Parker R.G.
        • Gallardo D.
        • Law J.
        Adjuvant radiation therapy after radical prostatectomy for carcinoma of the prostate.
        Am J Clin Oncol. 1997; 20: 120-124
        • Bolla M.
        • Collette L.
        • Blank L.
        • et al.
        Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
        Lancet. 2002; 360: 103-106
        • Pilepich M.V.
        • Winter K.
        • Lawton C.A.
        • et al.
        Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31.
        Int J Radiat Oncol Biol Phys. 2005; 61: 1285-1290
        • Messing E.M.
        • Manola J.
        • Sarosdy M.
        • Wilding G.
        • Crawford E.D.
        • Trump D.
        Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
        N Engl J Med. 1999; 341: 1781-1788
        • Corn B.W.
        • Winter K.
        • Pilepich M.V.
        Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group.
        Urology. 1999; 54: 495-502
        • King C.R.
        • Presti Jr., J.C.
        • Gill H.
        • Brooks J.
        • Hancock S.L.
        Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?.
        Int J Radiat Oncol Biol Phys. 2004; 59: 341-347
        • Eulau S.M.
        • Tate D.J.
        • Stamey T.A.
        • Bagshaw M.A.
        • Hancock S.L.
        Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
        Int J Radiat Oncol Biol Phys. 1998; 41: 735-740
        • Cheung R.
        • Kamat A.M.
        • de Crevoisier R.
        • et al.
        Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy.
        Int J Radiat Oncol Biol Phys. 2005; 63: 134-140
        • Hayes S.B.
        • Pollack A.
        Parameters for treatment decisions for salvage radiation therapy.
        J Clin Oncol. 2005; 23: 8204-8211
        • Valicenti R.K.
        • Gomella L.G.
        • Ismail M.
        • et al.
        Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose.
        Urology. 1998; 52: 1034-1040
        • Wong G.W.
        • Palazzi-Churas K.L.
        • Jarrard D.F.
        • et al.
        Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
        Int J Radiat Oncol Biol Phys. 2008; 70: 449-455
        • Wiltshire K.
        • Brock K.
        • Haider M.
        • et al.
        Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy.
        Int J Radiat Oncol Biol Phys. 2007; 69: 1090-1099
        • Connolly J.A.
        • Shinohara K.
        • Presti Jr., J.C.
        • Carroll P.R.
        Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins.
        Urology. 1996; 47: 225-231
        • Roach 3rd., M.
        • DeSilvio M.
        • Lawton C.
        • et al.
        Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
        J Clin Oncol. 2003; 21: 1904-1911
        • Cozzarini C.
        • Bolognesi A.
        • Ceresoli G.L.
        • et al.
        Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients.
        Int J Radiat Oncol Biol Phys. 2004; 59: 674-683
        • Catalona W.J.
        • Smith D.S.
        Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results.
        J Urol. 1998; 160: 2428-2434
        • Parker C.
        • Clarke N.
        • Logue J.
        • et al.
        RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).
        Clin Oncol (R Coll Radiol). 2007; 19: 167-171
      3. Trans-Tasman Radiation Oncology Group ‘RAVES’ trial (Radiotherapy – Adjuvant Versus Early Salvage), personal correspondence with Dr. Maria Pearce, New Zealand: Auckland Hospital.